Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1653 1654 1674
This examiner grants 64% of resolved cases
Claire M Kaufman works in Tech Center 1600 and Art Unit 1646. With 573 resolved cases, she has established an allowance rate pct of 63.5. This 63.5 allowance rate pct indicates the frequency of grants for applications on her docket. The 573 resolved cases provide a data set for understanding the examination process in Art Unit 1646.
The interview lift pct is 50.7. This 50.7 interview lift pct shows the correlation between interviews and the probability of allowance. Practitioners should note the 50.7 figure when deciding on a prosecution strategy. The 50.7 interview lift pct suggests that direct engagement is a factor in reaching a resolution in Tech Center 1600.
The median days to allowance is 1090. This 1090 median days to allowance represents the time from filing to the issuance of a patent. The 1090 figure is a metric for the duration of the prosecution process. For those in Art Unit 1646, the 1090 median days to allowance provides a timeline for the duration of successful applications.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17416403 | METHOD OF TREATING CANCER USING A HISTONE ACETYLTRANSERACE ACTIVATOR WITH IFN¿ AND AN IMMUNE CHECKPOINT INHIBITOR | Non-Final OA | The Regents of the University of California |
| 18392954 | ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES | Final Rejection | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18666545 | CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS | Final Rejection | Bayer Aktiengesellschaft |
| 18666512 | CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS | Final Rejection | Bayer Aktiengesellschaft |
| 18583551 | BLOCKADE OF CD7 EXPRESSION AND CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY OF T-CELL MALIGNANCIES | Non-Final OA | National University of Singapore |
| 18567967 | POLYPEPTIDES TARGETING CD70-POSITIVE CANCERS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18175225 | METHOD OF TREATMENT OF PATIENTS HAVING REDUCED SENSITIVITY TO A BCL-2 INHIBITOR | Non-Final OA | The Regents of the University of Colorado, A Body Corporate |
| 18019467 | TREATMENT OF CLL | Final Rejection | NOVARTIS AG |
| 18002368 | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTI-TL1A ANTIBODIES | Non-Final OA | Pfizer Inc. |
| 17921793 | PHARMACEUTICAL FORMULATION | Final Rejection | AMGEN INC. |
| 17774232 | MULTITARGETING ANTIGEN-BINDING MOLECULES FOR USE IN PROLIFERATIVE DISEASES | Non-Final OA | AMGEN INC. |
| 17907312 | TNFa SIGNALING TRIGGERS TUMOR-PROMOTING INFLAMMATION THAT CAN BE TARGETED TO THERAPY | Final Rejection | Baylor College of Medicine |
| 18019612 | COMBINED MEDICATION FOR TREATING SOFT TISSUE SARCOMA | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18140141 | METHODS OF TREATING LYMPHOPENIA | Non-Final OA | Keros Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy